AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 02. February ,2026

MYOCARDIAL INFARCTION: AN IN-DEPTH OVERVIEW OF CAUSES, MECHANISMS, AND CURRENT TREATMENT APPROACHES

Nuriddinov Umed Zayniddin ugli
Asia International University,Bukhara,Uzbekistan

Abstract

Myocardial infarction (MI), commonly known as a heart attack, occurs when there is a sustained interruption in coronary artery blood flow, resulting in permanent damage and death of cardiac muscle cells (cardiomyocytes). Even with major progress in catheter-based interventions, MI continues to be a leading cause of death worldwide and significant long-term impairment. This article examines the root causes, underlying biological processes, and up-to-date, evidence-supported treatments. Particular attention is given to drug-based regimens and strategies for prevention to enhance survival and quality of life.

1. Introduction

Acute myocardial infarction (AMI) is among the most urgent time-critical conditions encountered in medical practice. Patient outcomes hinge critically on how quickly the condition is identified and reperfusion treatment is started. A thorough grasp of the interactions among inherited risks, daily habits, and the molecular events during oxygen deprivation is crucial for crafting successful therapies and strategies to avoid future episodes.

2. Causes of Myocardial Infarction

The main underlying factor in MI is coronary atherosclerosis. This usually involves abrupt disruption (rupture or erosion) of an unstable plaque containing substantial lipids, exposing highly thrombogenic substances to circulating blood and initiating a swift clotting process that partially or fully blocks the artery.

Additional causes encompass:

Coronary artery spasm: Abrupt narrowing of the vessel due to muscular contraction.

Embolic events: Clots or other material dislodged from distant sites lodging in coronary vessels.

Type 2 MI: Imbalance in myocardial oxygen supply versus demand, often triggered by conditions such as profound anemia, rapid heart rates, or lung failure.

Key risk contributors include high blood pressure, diabetes, elevated blood lipids, cigarette smoking, physical inactivity, and excess body weight.

3. Mechanisms of Development

The biological progression of MI involves a cascade of biochemical and structural alterations:cIschemia onset: Almost immediately after flow cessation, the myocardium shifts to anaerobic metabolism.

Energy crisis: Rapid exhaustion of ATP reserves impairs ion transport mechanisms (such as the sodium-potassium pump), causing cell swelling and acid buildup inside cells.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 02. February ,2026

Cell death: Without reperfusion within roughly 20–40 minutes, irreversible damage sets in (typically coagulative necrosis), beginning in the inner layers (subendocardium) and extending outward.

Subsequent inflammation: In the recovery phase, immune cells like neutrophils and macrophages arrive to remove dead tissue, culminating in replacement by a fibrous scar over time.

4. Contemporary Management Strategies

The central principle in current care is encapsulated by the phrase "Time is Muscle," stressing the urgency of restoring circulation to limit damage. Reperfusion Strategies: Primary percutaneous coronary intervention (PCI) serves as the preferred method when achievable within 90–120 minutes from initial medical evaluation. In settings without timely PCI access, fibrinolytic (clot-dissolving) drugs offer a viable substitute.

Drug Therapy: A combination regimen is standard to stabilize the acute phase and reduce future risks.

Drug Class	Drug Name	Dosage	Clinical Purpose
Antiplatelet	Aspirin	Loading: 150–325 mg orally; Maintenance: 75–100 mg daily	Inhibition of platelet aggregation
Antiplatelet	Clopidogrel	Loading: 300–600 mg; Maintenance: 75 mg daily	P2Y12 receptor inhibition
Anticoagulant	Unfractionated Heparin	Bolus: 60–70 IU/kg (max 5000 IU); Infusion: 12–15 IU/kg/h	Prevention of thrombus propagation
Beta-blocker	Metoprolol	IV: 5 mg every 5 min up to 15 mg; Oral: 50–100 mg twice daily	Reduction of myocardial oxygen demand
ACE Inhibitor	Enalapril	2.5–20 mg daily	Prevention of ventricular remodeling
Statin	Atorvastatin	40–80 mg daily	Lipid lowering and plaque stabilization
Nitrate	Nitroglycerin	0.4 mg sublingual every 5 min (max 3 doses)	Relief of ischemic chest pain

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 02. February ,2026

(Note: Dosages and choices may vary based on patient factors and the latest 2025 ACC/AHA guidelines, which emphasize preferences like ticagrelor over clopidogrel in many PCI cases and high-intensity statins for all.)

5. Preventive Measures

Prevention divides into:

Primary prevention: Targeting at-risk but unaffected individuals through lifestyle adjustments (healthier eating, regular activity, quitting smoking) and aggressive control of modifiable risks to avert initial events.

Secondary prevention: Rigorous ongoing therapy, lifestyle support, and structured cardiac rehab programs for those who have survived MI to lower chances of recurrence, heart failure, or other complications.

6. Conclusion

Despite substantial declines in immediate death rates thanks to advanced PCI techniques and improved medications, myocardial infarction persists as a major worldwide health burden. Sustained emphasis on long-term care for survivors—through optimal medical therapy, rehabilitation, and widespread adoption of heart-protective habits—offers the greatest potential to curb the impact of coronary artery disease.

References

1. Thygesen, K., et al. (2018). Fourth Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology.
2. Ibanez, B., et al. (2017). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal.
3. Libby, P. (2021). The changing landscape of atherosclerosis. Nature.
4. Heidenreich, P. A., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation.
5. Rao, S.V., et al. (2025). 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology / Circulation